IL6 and Neurodevelopmental delay: Tocilizumab has also been tested in ALS [112] and proposed in PD [100] and AD [91] As IL-6 is present in the CSF, monoclonal antibodies binding IL-6 directly—such as HZ-0408b [126]—via IT pseudodelivery might be an alternative route to target inflammation in NDD.